Etokimab

Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1.1% of U.S. adults, impairing quality of life. FDA-approved biologics (dupilumab, mepolizumab, omalizumab) target type 2 inflammation, showing efficacy in reducing polyp size and improving symptoms. Optimal use, treatment duration, and patient selection for biologics remain unclear, necessitating further research and shared decision-making.

AnaptysBio's Q3 2024 10-Q report shows collaboration revenue up to $30.0M, with a net loss of $(32.9)M. The company advances its pipeline, including rosnilimab in Phase 2b for RA and UC, and ANB032 in Phase 2b for AD. Challenges include product development risks and regulatory approval hurdles.

Top-line Phase 2b data for ANB032 (BTLA agonist) in atopic dermatitis expected Dec 2024, rosnilimab (PD-1 agonist) in rheumatoid arthritis in Feb 2025. Phase 1 trial initiated for ANB033 (anti-CD122 antagonist). Cash runway reiterated through year-end 2026.